Supplementary methods

Growth curves and drug sensitivity
To obtain growth curves, 1x10 5 cells were plated in triplicates for each time point in 6-well plates; each day cells were trypsinized and counted in triplicates. For drug sensitivity assays, cells were plated in triplicates in 96-well plates (2x10 3 cells/well) and were treated with serial dilutions of either etoposide (starting concentration 5uM) or hydroxyurea (starting concentration 500uM). For sensitivity of cells to Holliday Junction-binding peptide wrwycr, cells were treated with serial dilutions of the peptide (starting concentration 40 mkM) for 24h or 72h; cells treated for 24h were allowed to grow for additional 48h in drug-free medium before analysis. Cell viability was assessed using CellTiter-Blue® Cell Viability Assay (Promega).
Nuclear morphology
Nuclear morphology was studied in cells that were fixed with 4% formaldehyde and were stained with 100g/ml DAPI (Molecular Probes, #D1306). Nuclei were observed by the fluorescent microscope equipped with digital camera; pictures were taken at either 20x, 40x or 63x magnification using Q-Capture Pro7 software. Nuclear sizes were analyzed using ImageJ software. For each DAPI-stained nucleus, integrated intensity of fluorescence was measured.
DHFR copy number analyses
DHFR copy number was measured using quantitative real time PCR using Light Cycler 480 (Roche, Indianapolis, IN, USA). Genomic DNA was extracted from cells as described Kondratova et al. previously. Briefly, cells were incubated in the lysis buffer (100mM NaCl/10mM Tris⋅HCl, pH 8.0/25mM EDTA/0.5%SDS/proteinase K) for 24 hours at 37°C, followed by phenol/chloroform extraction and ethanol precipitation. PCR primers were designed for DHFR cDNA in the transgene and copy numbers were normalized to the internal control Chinese hamster p53. PCR reactions were carried out in a three-step 40-cycle reaction of 95°C for 30 seconds, 60°C for 3 seconds, and 72°C for 30 seconds by using iQ SYBR Green Supermix (Bio-Rad, Hercules, CA, USA). We used 5 ng/μl of genomic DNA for each reaction.
Southern blotting was done as described previously (references 8,9). 2g of genomic DNA was digested with PstI and NheI, run on a 0.8% agarose gel and transferred onto nylon membrane. Probes (DHFR cDNA and Chinese hamster p53) were labeled with 32 P and cohybridized to the membranes. 
STDEV, standard deviation Experimental procedure
Either 10 5 (for 0.8M MTX) or 10 4 cells (for 0.4M MTX) were plated into a 10cm 2 plate and, on the next day MTX was added to the media. Media and MTX were replaced every four days. After 12 days of selection, colonies on the plates were fixed and stained.
Supplementary table 1
The number of MTX resistant colonies from 5 genotypes (Fig. 1D 
Caffeine treatment
The following day, caffeine was added into the three of 6 plates.
MTX and Caffeine treatments
The following day, media was replaced with the one with 0.4M MTX. Caffein was added to the three plates. The treatment was repeated every four days.
4. After 12 days of MTX selection, plates were stained with crystal violet.
Supplementary table 3
Colony count Expression vector with caffeine without caffeine Sce-1  32  7  Sce-2  34  9  Sce-3  38  14  GFP-1  3  0  GFP-2  3  2  GFP-3  4  3 Supplementary table 4 Supplementary table 4   2   GO:0006694  steroid biosynthetic process  9.97E-12  CYB5R3, CYP51, HSD3B2, EBP, SC5D, MVD, HMGCS1, FDPS, LSS, FDFT1, SC4MOL, INSIG2,  PXMP3, INSIG1, SRD5A1, IDI1, DHCR24, NSDHL  GO:0016125  sterol metabolic process  3.10E-08  CYB5R3, CYP51, EBP, SC5D, MVD, HMGCS1, FDPS, FDFT1, SC4MOL, SREBF2, INSIG2, INSIG1,  IDI1, DHCR24, NSDHL  GO:0008203  cholesterol metabolic process  5.92E-07  CYB5R3, CYP51, EBP, MVD, HMGCS1, FDPS, FDFT1, SREBF2, INSIG2, INSIG1, IDI1, NSDHL,  DHCR24  GO:0008610  lipid biosynthetic process  6.53E-07  CYB5R3, CYP51, HSD3B2, SC5D, PTGS2, MVD, HMGCS1, LSS, SC4MOL, FDFT1, INSIG2, ANG CCL2, C3, LY96, CXCL3, PPARG, TLR1, F8, IL25, SAA3, TLR3, C1RA, NOD2, NUPR1, CCL20,  C1RL, SCN9A, CFH, VNN1, CR1L  GO:0009611  response to wounding  1.62E-04  NFKBIZ, CCL2, C3, LY96, CXCL3, PPARG, F2RL1, TLR1, NINJ2, F8, IL25, SAA3, GJA1, TLR3, C1RA,  NOD2, NUPR1, CCL20, C1RL, SCN9A, CFH, VNN1, LCP1, CR1L  GO:0045087  innate immune response  2.37E-04  C1RA, TMEM173, NOD2, C3, CEBPG, TLR1, C1RL, CFH, TLR3, VNN1, PRDX1, CR1L  GO:0006955  immune response  4.72E-04  MFSD6, CCL2, C3, CXCL3, TLR1, TNFSF15, TLR3, ACP5, BNIP3, PRDX1, LIF, C1RA, TMEM173,  NOD2, CCL20, SQSTM1, CFH, VNN1, H2-K1, LY96, CEBPG, ZFR2, BCAP31, LAT2, VAMP7, C1RL,  LCP1, CR1L   3   GO:0008285  negative regulation of cell proliferation  2.46E-04  PTGS2, PPARG, NDFIP1, PAWR, SFN, CTNNA1, DDR1, SPRY2, CDKN1A, SPRY1, EREG, SERPINF1,  NUPR1, CDKN2C, ANG, TGIF1, ATPIF1, TES  GO:0042127  regulation of cell proliferation  7.92E-04  SAT1, CCL2, PTGS2, IL6ST, PPARG, PAWR, SFN, LIF, SPRY2, SPRY1, CDKN2C, ANG, TGM2,  FGFBP1, TES, IRS2, CRIP2, NDFIP1, ANXA1, CTNNA1, ATF5, DDR1, CDKN1A, EREG, SERPINF1,  NUPR1, DBP, SERPINB5, TGIF1, ATPIF1 regulation of cell proliferation GO-ID and clusters 
